Interim PET-adapted de-escalation chemotherapy regimen for advanced stage classical Hodgkin lymphoma using brentuximab vedotin, pembrolizumab, doxorubicin, and dacarbazine: Phase 2 study
Year: 2025
Type: conference-abstract
Source: Blood
Authors: Hun Lee, Gregory Ravizzini, Jenna Wixom, Ayushi Chauhan, Luis Fayad, Ranjit Nair, Jason Westin, Jared Henderson, Eslam Aboismail, Christopher Flowers, Michael Wang, Luis Malpica Castillo
Institution: The University of Texas MD Anderson Cancer Center
Language: English
Subfield: Pathology and Forensic Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W7108615729